Verastem/$VSTM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Verastem
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
Ticker
$VSTM
Sector
Primary listing
Employees
78
Headquarters
Website
Verastem Metrics
BasicAdvanced
$598M
-
-$3.52
0.83
-
Price and volume
Market cap
$598M
Beta
0.83
52-week high
$11.25
52-week low
$2.54
Average daily volume
2.8M
Financial strength
Current ratio
3.46
Quick ratio
3.308
Long term debt to equity
223.366
Total debt to equity
234.954
Interest coverage (TTM)
-58.03%
Profitability
EBITDA (TTM)
-156.407
Gross margin (TTM)
85.12%
Net profit margin (TTM)
-7,793.87%
Operating margin (TTM)
-7,326.11%
Effective tax rate (TTM)
-0.11%
Revenue per employee (TTM)
$30,000
Management effectiveness
Return on assets (TTM)
-64.80%
Return on equity (TTM)
-437.92%
Valuation
Price to revenue (TTM)
238.276
Price to book
16.59
Price to tangible book (TTM)
29.29
Price to free cash flow (TTM)
-4.235
Free cash flow yield (TTM)
-23.61%
Free cash flow per share (TTM)
-2.295
Growth
Revenue change (TTM)
-78.63%
Earnings per share change (TTM)
5.62%
3-year revenue growth (CAGR)
-12.07%
3-year earnings per share growth (CAGR)
-12.01%
10-year earnings per share growth (CAGR)
-17.03%
What the Analysts think about Verastem
Analyst ratings (Buy, Hold, Sell) for Verastem stock.
Bulls say / Bears say
AVMAPKI™ FAKZYNJA™ CO-PACK (avutometinib + defactinib) received accelerated FDA approval on May 8, 2025 as the first treatment specifically for KRAS-mutated recurrent low-grade serous ovarian cancer, securing a first-mover position in the indication (Business Wire)
Updated RAMP 205 Phase 1/2 data announced May 22, 2025 showed an 83% overall response rate (10/12) at the selected Phase 2 dose in frontline metastatic pancreatic ductal adenocarcinoma, underpinning plans for a registrational Phase 3 trial (Business Wire)
As of June 30, 2025, Verastem held $164.3 million in cash and cash equivalents, with product revenue and warrant exercises extending the company’s cash runway into the second half of 2026, supporting continued R&D and commercialization efforts (SEC)
Despite the May 8 launch, net product revenue for AVMAPKI™ FAKZYNJA™ CO-PACK was only $2.1 million in the first six weeks, indicating limited initial commercial uptake relative to the company’s high fixed R&D and G&A costs (SEC)
The January 13, 2025 debt financing with Oberland Capital, featuring up to $150 million of notes and revenue participation payments of 1% on the first $100 million of annual net sales, increases financial leverage and could pressure future cash flows and margins (Business Wire)
Low-grade serous ovarian cancer accounts for only 5%–10% of serous ovarian cancers, with roughly 2,000 new U.S. cases annually, constraining the addressable market and peak revenue potential for AVMAPKI™ FAKZYNJA™ CO-PACK (American Journal of Managed Care)
Data summarised monthly by Lightyear AI. Last updated on 4 Sept 2025.
Verastem Financial Performance
Revenues and expenses
Verastem Earnings Performance
Company profitability
Verastem News
AllArticlesVideos
Verastem Oncology to Present at Upcoming Investor Conferences
Business Wire3 weeks ago
Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics' Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer
Business Wire1 month ago
Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025
Business Wire2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Verastem stock?
Verastem (VSTM) has a market cap of $598M as of September 15, 2025.
What is the P/E ratio for Verastem stock?
The price to earnings (P/E) ratio for Verastem (VSTM) stock is 0 as of September 15, 2025.
Does Verastem stock pay dividends?
No, Verastem (VSTM) stock does not pay dividends to its shareholders as of September 15, 2025.
When is the next Verastem dividend payment date?
Verastem (VSTM) stock does not pay dividends to its shareholders.
What is the beta indicator for Verastem?
Verastem (VSTM) has a beta rating of 0.83. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.